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Abstract. Glutathione S-transferases (GSTs) are a family o f stomach wall* The diffuse cancer has a poorer prognosis and 
isoenzymes that play an important role in protecting cells against is more common in women and younger patients (4).
cytotoxic and carcinogenic agents. Biotransformation enzymes, and in particular glutathione S-
The distribution and levels o f GST Alpha and Pi in nonnal transferases (GSTs) are present in most epithelial tissues of
and malignant gastric tissue o f 34 patients with gastric cancer the human gastrointestinal tract (5-8). Their presumptive
were examined immunohistochemically. Expression o f GST  function is to protect tissues against toxic or carcinogenic
Alpha and Pi was obseived in 47 and 100 percent o f (he tumors, compounds, entering the body as food components, food
respectively. In normal mucosa both enzyme classes were present additives or drugs (5,9). Four classes of cytosolic GST
in 100 percent o f the specimens. Mucous cells showed staining isoenzymes exist in man: Alpha, Mu, Pi and Theta (10,11).
for G ST Alpha and Pi in 88 and 97 percent, parietal cells in 93 
and 67 percent, and chief cells in 82 and 30 percent, respectively, 
No correlation was observed between the amount or pattern o f 
G ST Alpha or Pi in carcinomas and the clinical and 
pathological characteristics o f the. patients. .SV; it can be 
concluded that both GST Alpha and Pi cannot he considered as 
progn os tic jdctoi s for gastric ca /1 cer.
The incidence and mortality associated with gastric 
adenocarcinoma has decreased in many countries during the 
past five decades (1). However, despite new diagnostic and 
therapeutic techniques, the 5-year survival rate of patients 
with advanced stage of gastric adenocarcinoma continues to 
be poor (2).
Two main histological types of gastric carcinoma were 
characterized by Lauren (3), the intestinal type, resembling 
small bowel mucosa; and the diffuse type, infiltrating the
Expression of class Alpha and Pi enzymes is different in the 
various tissues. For instance, class Alpha enzymes are present 
in high levels in the liver (12,13), stomach (14) and small 
intestine (15), while class Pi enzymes are expressed in many 
organs, other than the adult liver (16,17). Increased 
expression of class Pi enzymes has been reported in a wide
of human tumors, compared to the normal 
surrounding tissue (17-21). Interestingly, GST Pi expression 
in patients with node negative breast cancer (22) has been 
reported as a prognostic factor recently. To better understand 
the role of GSTs in gastric cancer and to study whether they 
have a predictive value, immunohistochemical expression of 
GST class Alpha and Pi was studied in gastric carcinoma and 
adjacent normal mucosa, in relation to patient and tumor 
characteristics, such as tumor type, stage, and the length of 
survival.
Patients and Methods’
Corrospondence to: D.L. Schipper, MD, Department of Medical 
Oncology, University Hospital Nijmegen, PO Box 9101, 6500 
HB Nijmegen, The Netherlands. Phone 31 -24-3615215. Fax 31- 
24-3540788.
Key Words: Glutathione S-transferase, gastric carcinoma, normal 
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Patients and tumor samples. Tumor specimens and normal gastric tissue 
from 34 patients, who underwent primary surgery for gastric eancer 
between lc)85 and were included in this study. Fnticnl dal a are 
summarized in Table 1. Tumor stage was classified according to the 
criteria of the American Joint Committee on Cancer (23).
Selection for this study was based on the following criteria: formalin- 
fixed, paraffin-embedded specimens with ho 111 assessable minor and 
normal mucosa must be available, patients must have undergone primary
0250-7005/96 $2.00+ .40
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I ahle I. Patient characteristics (n = 3 4 ) .
Age (years)
xi um
Range
66
43-76
Sex
Male
Female
18
16
1 u mor Stage 
Stage I
Stage II 
Stage IIÏ 
Stage IV
9
1.1
7
I’umor differentiation 
Undifferentiated 
Poorly differentiated 
Moderately differentiated 
Well differentiated
3
19
1Ü
Lauren Classification 
Diffuse 
Intestinal 
Indeterminate
13
17
Survival (months) 
Median 
Ra nge
20
0- > 104
surgery, and clinical information of status at presentation and follow-up 
must he available. The study was approved by the local ethical 
committee on human experimentation.
lnwutnohistoclunnical staining. From each specimen three 4 |Lim thick 
slices were used: one for standard haematein eosin staining and two for 
immunohistochcmical investigation of GST class Alpha and Pi. For 
immunohisioehemical assays, sections of formalin-fixed paraffin- 
embedded tissue were dewaxccl in xylol, rehydrated in ethanol and 
immersed in methanol with 2% hydrogen peroxide for 10 minutes to 
block endogenous peroxidase activity. Subsequently the sections were 
p re incubated with phosphate-buffc red-saline (PBS) containing 4% 
bovine serum albumin (BSA; Boehringer, Mannheim, Germany) and
0.1% Triton X-100 (BDH Chemicals Ltd., Poole, England) to block 
nonspecific binding. The slides were incubated overnight at 4°C with 
primary antibodies against GST class Alpha (monoclonal antibody), as 
developed by us recently (Peters el al, 1992), diluted 1:5000 in PBS 
containing 4% BSA and 0.1% Triton X-100 (buffer A) and GST class Pi 
(polyclonal antibody, Biotrin International, Dublin, Ireland) diluted 
1:2400 in buffer A. Subsequently a 45 minute incubation period at room 
temperature with peroxidase conjugated rabbit-anti-mouse immuno­
globulin (Dakopatts, G lost r up, Denmark) diluted 1:100 in buffer A or 
peroxidase conjugated swine-anti-rabbit immunoglobulin (Dakopatts)
Table II. Proporlion o f  celis showing sta ini ng far G S T  Alpha and Pi in 
norma! and neoplasti c gas tri c tissue.
Category * 0 1 2 3 4 5 Total
GST Alpha
Tumor cells 18 1 4 3 1 7 34
Mucous cells 4 1 1 7 3 17 33
Parietal cells 2 0 4 1 4 17 28
Chief cells 5 3 9 4 4 3 28
GST Pi
Tumor cells 0 0 3 3 5 23 34
Mucous cells 0 0 0 1 2 30 33
Parietal cells 9 7 4 5 2 0 27
Chief cells 19 4 1 2 1 0 27
* Categories explained in Materials and Methods.
The numbers indicate the number of cases falling into each category.
diluted 1:40 in buffer A was performed for GST Alpha or Pi 
immunodetection, respectively. In order to enhance the intensity of the 
final staining a third incubation step was used: peroxidase conjugated 
swine-anti-rabbit immunoglobulin (Dakopatts) diluted 1:40 in buffer A 
for GST class Alpha and peroxidase conjugated rabbit-anti-mouse 
immunoglobulin (Dakopatts) diluted 1:100 in buffer A for GST class Pi. 
Staining was performed using 0.1% 3,3- diaminobenzidine (Sigma 
Chemical Company, St. Louis, MO, USA) in PBS containing 0.01% 
hydrogen peroxide as peroxidase substrate. The slides were 
counterstained with haematein. Between each step the sections were 
washed three times each for 5 minutes in PBS.
Human liver tissue and human colon tissue were used as a positive 
control for GST Alpha and Pi, respectively. Omission of primary 
antibodies served as negative controls.
Scoring. Both the intensity of staining and the proportion of stained cells 
were scored by three independent individuals. The intensity of staining 
was graded as follows: (-) negative, (4-) weakly positive, (+ + ) 
moderately positive, (+ + + ) strongly positive. The proportion of cells 
showing staining was scored as follows: (0) <1 percent stained cells, ( I ) 
1-5 percent stained cells, (2) 6-25 percent stained cells, (3) 26-50 percent 
stained cells, (4) 51-75 percent stained cells, (5) >75 percent stained 
cells. The distribution of staining was assessed by scoring tumor cells, 
mucous cells, parietal cells and chief cells, separately.
Statistics. Correlation between parameters was evaluated using the 
Spearman rank correlation test. In order to evaluate the differences in 
expression of the various cell types Friedman two-way Anova was used. 
In case of significant results (p < 0.05) it was followed by the sign test. 
Kaplan Meier survival functions were constructed, and the relation 
between survival and expression of GST Alpha and Pi was analyzed 
using the generalized Wilcoxon test. Localization of the tumor, age, 
tumor differentiation grade and Lauren classification were included as 
covariates in the analysis.
Results
GST Alpha. The results of scoring the proportion of cells 
staining for GST Alpha are summarized in Table II while 
intensity of staining is reported in Table III.
SchippercV al: Glutathione S-Transfc a  iso s in Gastric Cm n cor
GST Alpha was present in 16 carcinomas (47 percent).
Staining was generally focal and cytoplasmatic with staining of 
more than half the tumor cells in only 8 cases (Figure la).
The adjacent normal mucosa showed positive immuno- 
reactivity in all cases (Figure lb). Mucous cells were present 
in 33 specimens. Positive immunostaining of mucous cells was 
seen in 29 specimens (88 percent). In 20 sections (61 percent) 
more than half of the mucous cells gave positive staining.
Staining was predominantly cytoplasmatic and localized both 
in surface epithelium and in cells localized deeper within the 
crypts. In areas with intestinal metaplasia all affected cells 
showed very strong immunoreactivity (Figure lc). Parietal 
cells were seen in the normal mucosa of 28 cases. In 26 cases 
(lJ3 percent) they showed diffuse cytoplasmatic and nuclear 
positivity for GST Alpha. Strongly positive immunoreactivity 
with dark staining of more than half the parietal cells was 
present in 21 cases (75 percent).
Chief cells were present in 28 sections and positive staining 
was observed in 23 sections (82 percent), with a generally 
weak to moderate strong cytoplasmatic staining pattern.
Staining of more than 50 percent of the chief cells could be 
observed in only 7 cases (25 percent).
intensity of staining for GST Alpha and proportion of cells 
stained was significantly higher in parietal cells and in mucous 
cells than in chief cells and tumor cells (p < 0.05).
Connective tissue components (i.e. collagen, muscle etc.) positivity. 
were consistently negative.
CAST Pi Results of scoring the proportion of cells, staining for 
GST Pi are summarized in Table II, while intensity of staining 
is given in Table III.
In all cases carcinoma showed positivity for GST Pi.
Staining was predominantly cytoplasmatic, with additional 
nuclear staining in some cells (Figure Id). Staining intensity 
for GST Pi showed heterogeneity, showing tumor cells either 
negative, or positive with moderate to high intensity within 
the same tumor. In 28 cases (82 percent) more than half of 
tumor cells were positive.
Normal mucosa showed positive immunoreactivity in all Discussion 
cases. Mucous cells were positive in all sections In which they 
were present. In 32 cases (97 percent) more than half of the 
mucous cells were positive. The surface epithelium was 
strongly positive, while mucous cells located deeper within the 
crypts showed less intense staining (Figure le). In sections 
with intestinal metaplasia all affected cells showed 
immunoreactivity (Figure If).
Parietal cells stained positive in 18 of the 27 sections in 
which they were present (67 percent). Staining was generally 
weak to moderate, with more than 50 percent positive in only
Table III. Staining intensity o f  G ST  Alpha and Pi in normal and neoplastic 
gastric tissue.
Category* m + + + 4- + 4- Total
GST Alpha 
Tumor cells 18 2 y 5 34
Mucous cells 4 3 9 17 33
Parietal cells 
$
2 ,! ?4mé 23 28
Chief cells 5 12 10 1 28
GST Pi
Tumor cells 0 3 11 20 34
Mucous cells 0 1 12 20 33
Parietal cclls 9 11 4 3 27
Chief cells 1.9 6 0 27
* Categories explainccl in Materials and Methods.
The numbers indicate the number of eases hilling into each category.
were t consistently weakly positive. Plasma cells and 
lymphocytes showed strong nuclear and cytoplasmatic
Correlation between GST Alpha or Pi expression with clinical 
and pathological findings. In Table IV and V the clinical and 
pathological characteristics of the tumors are compared with 
the proportion of tumor cells with detectable staining for 
GST Alpha and Pi, respectively. There was no significant 
correlation between expression of GST Alpha or Pi and 
clinical stage, tumor differentiation and Lauren classification 
of the tumor (all p < 0.2). In addition, expression of GST 
Alpha or Pi in the tumor was not related with length of 
survival.
Gastric tumors arc known to contain GST activity and 
previous studies have indicated that most of them express 
GST Pi and to a lesser extent GST Alpha (14,17). However 
these studies were done on tissue homogcnates which 
inevitably contain non-neoplastic elements such as stroma 
and which may even contain normal mucosa. 
Immunohistochemical analysis of GST Pi in gastric carcinoma 
was performed by Tsutsumi et al (24). They described high 
levels of GST Pi in all except for signet ring cell carcinomas.
2 cases. Chief cells gave a weak immunoreactivity in only 8 of In our study GST Pi was detected in 100 percent of gastric
the 27 sections (30 percent) in which they were present.
Intensity of staining for GST Pi and the proportion of cells 
stained was significantly higher in mucous cells and in tumor 
cells than in chief cells and parietal cells (p < 0.05).
tumors, whereas GST Alpha was found in only 47 percent. In 
many tumors there was a high expression of GST Pi in the 
accompanying stromal cells and inflammatory infiltrate. Such 
observations emphasize the usefulness of immunohi-
Connective tissue components (i.e. collagen, muscle etc.) stochemical techniques in demonstrating the distribution of
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I. Immunos'taining o f  G S T  Alpha and Pi in gasine adenocarcinoma and gastric mucosa. Space bar—} 081 pm  A. 'Put nor cells (7’j, heterogeneously 
positive for G ST  Alpha in gastric carcinoma. II Normal gastric (issue showing strong positivity for GST Alpha in mucous cells (M) and parietal cells (P), 
while chief cells (C) were moderately positive. C. Intestinal metaplasia showing strong immunoreactivity for G ST Alpha. D. Diffuse staining for GST Pi in 
tumor cells (T). E. G ST Pi expression in normal gastric tissue, showing intense positivity in mucous cells (M ) . F. G ST Pi expression in intestinal 
metaplasia.
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'l’uble IV. Association o f  GS'T Alpha expression with clinical and  
pathological characteristics in 34 patients with gastric cancer;
Proportion of tumor cells showing 
expression of GST Alpha
Table V. Association o f  G S T  Pi expression with clinical and pathological 
characteristics in 34 patients with gastric cancer,
-____________ m __|----j _ r i ------------------1----------- ---------------------------------------------- i t— " ------------ — * ------------------------------- ---------------------------------------r  ^ -
Proportion of tumor cells showing 
expression of GST Pi
* Categories explained in Materials and Methods.
The numbers indicate the number of eases failing into each category,
Category* 0 1 2 3 4 5 Total Category* 0 1 2 3 4 5 Total
Stage
] 2 1 1 1 1 1 7
Stage
I 0 0 1 0 1 5 7
11 7 0 0 1 0 1 9 II 0 0 0 2 3 4 9
III 6 0 3 1 0 1 11 III 0 0 2 0 0 y il
IV 3 0 0 0 0 4 7 IV 0 0 0 1 I 5 7
Differentiation
undifferentiated 2 0 0 0 Í) I 3
Differentiation
undifferentiated 0 0 0 1 0 2 3
poorly differentiated 10 0 2 1 0 6 19 poorly differentiated 0 0 2 1 3 13
m o d e r a l e I y d i ffe re n t i a te d 5 0 2 2 1 0 10 moderately differentiated 0 0 1 0 I K 11)
well differentiated 1 1 0 0 0 0 2 well differentiated 0 0 0 1 1 0 2
Lauren classification 
diffuse 7 0 I 1 0 4 13
Lauren classification 
diffuse 0 0 2 2 I 8 13
intestinal 7 1 3 2 1 3 17 intestinal 0 0 1 1 3 12 17
indeterminate 4 0 0 0 0 0 4 indeterminate 0 0 0 0 1 3 4
Survival, months 
< 13 7 0 2 0 1 I 11
Survival, months 
< 13 0 0 2 1 0 9 12
13-24 3 0 1 1 0 3 8 I 3-24 0 0 0 1 3 3 7
25-36 1 0 0 0 0 0 1 25-36 0 0 t) 0 0 1 1
>36 7 1 1 2 0 3 14 >36 0 0 1 1 i 10 14
* Categories explained in Materials and Methods.
The numbers indicate the number of cases falling into each category.
enzymes and other proteins in tissues and tumors, composed 
of a variety of different cell types.
Knowledge of the distribution of GST tissue may improve 
our understanding of their function. For example, what is the 
reason for the high expression of GST Alpha found especially 
in parietal cells, and of GST Pi in mucous cells of the surface 
epithelium? Furthermore, the biological significance of the 
heterogeneity in distribution of GST isoenzymes in gastric 
cancer is unclear. Intra-tumor variation of GSTs was also 
described in immunohistochemical studies on human 
carcinomas of the cervix (25), esophagus (8), breast (22) and
Immunohistochemical techniques also provide information 
on intracellular localization, Antibodies against GST Alpha 
and Pi gave both cytoplasiuatic and nuclear staining, which 
has also been described in immunohistochemical studies of 
GSTs in the esophagus (8), cervix (28) and breast (29). The 
significance and function of the nuclear localization is unclear 
and remains to be clarified.
In contrast to the results of Gilbert et al (22) for breast 
cancer patients, in patients with gastric carcinoma no 
apparent correlation of GST Alpha or Pi expression with 
clinicopathological features or survival could be detected. The
kidney (26). This variation causes a complicating feature in high levels of GST Pi in all normal mucosa specimens
the interpretation of GST expression. Until now there was no investigated suggests that GST Pi expression is not directly
evidence concerning the heterogeneity of GST in gastric related to malignancy in gastric cancer. However it should be
tumors. Since GST activity may be relevant for detoxification noted that the normal gastric mucosa used in this study was
of antineoplastic drugs (18) the variability of GST expression obtained from patients with gastric carcinoma, Although
suggests that different parts of the same tumors may have these tissues were microscopically normal, it is possible that
varying response to chemotherapy. In addition glutathione, (part of) the tissue already has undergone changes in GST Pi
the cofactor for GSTs (9), is known to have a 2-3 fold expression. Therefore the examination of normal gastric
variation in concentration within a single tumor (27). tissue from patients without gastric diseases would help to
Schipper eUÜ: Glutathione S-Transite rases in Gastric Cancer
resolve this question. Further investigations are now been 
carried out to clarify the significance and function of the 
heterogeneous GST expression in normal gastric tissue and in 
gastric carcinoma, especially in relation to anti-cancer drug 
resistance.
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